Given that ovarian cancer was associated with the number of TP53 mutations as well as the size of mutant clones, we reasoned that TP53 MB should be the best metric to discriminate patients with and without ovarian cancer because it counts not only the number of mutated positions, but the number of mutant molecules in each position, reflecting both number and size of clones. This evidence concerns the gene TP53 and ovarian carcinoma.